Streetbeat News

Stock Prices

WAY

Trading halt status was updated at 10:10:00 AM ET for an IPO security, which has now been released for quotation.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 2:10 pm

AAPL

Apple Inc. (NASDAQ:AAPL) is set to reveal its AI strategy, 'Apple Intelligence,' at the WWDC 2024. The AI features will be integrated into various Apple devices and apps, focusing on enhancing customer experience with a strong emphasis on user privacy and security. The event will also showcase other software upgrades and potentially provide insights into upcoming hardware releases.

Portfolio Pulse from Rounak Jain

June 07, 2024 | 2:08 pm

NIO

NIO Inc. (NYSE:NIO) shares are trading slightly higher after reporting fiscal Q1 2024 revenue of $1.37 billion, which missed analyst estimates and marked a significant decline year-over-year and quarter-over-quarter. The company also reported an adjusted loss per share of $0.33, slightly worse than analyst expectations. Additionally, NIO has entered into a charging network-sharing partnership with GAC Group, aiming to enhance charging services and interoperability.

Portfolio Pulse from Nabaparna Bhattacharya

June 07, 2024 | 2:05 pm

RAPP

Rapport Therapeutics has set its IPO price at $18 per share, with an offering of 8 million shares priced at $17 each.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 2:01 pm

WEX

WEX (NYSE:WEX) has significantly outperformed the market over the past 15 years, achieving an average annual return of 43.92%. A $100 investment in WEX 15 years ago would be worth $23,532.01 today. The article highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

June 07, 2024 | 2:00 pm

AMAT

Applied Mat (NASDAQ:AMAT) has significantly outperformed the market over the past 5 years, with an annualized return of 38.61%. A $100 investment in AMAT 5 years ago would be worth $518.90 today.

Portfolio Pulse from Benzinga Insights

June 07, 2024 | 2:00 pm

RGNX

Regenxbio (NASDAQ:RGNX) has received mixed ratings from 4 analysts, all of whom are bullish. The average 12-month price target has increased to $38.00, with a high of $40.00 and a low of $36.00. Despite facing revenue growth challenges, Regenxbio's net margin, ROE, and ROA surpass industry standards, although it has a higher debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

June 07, 2024 | 2:00 pm

SPY

Wholesale inventories for April increased by 0.1%, falling short of the 0.2% estimate and showing a decrease from the previous month's -0.4%.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 2:00 pm

C

SPY

Citi has revised its forecast for the first Federal Reserve rate cut, moving it from July to September. This change could impact financial markets and investor sentiment.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 1:57 pm

UBER

Uber's stock surged over 7% following the approval of its license to operate in Aberdeen, marking a 12% increase for the year. This move is seen as a positive step to address transportation issues in the city and reflects growing investor confidence.

Portfolio Pulse from Zaheer Anwari

June 07, 2024 | 1:57 pm